9 results about "Imipenem" patented technology

The invention belongs to the technical field of pharmaceutical chemical processes, and particularly relates to a preparation method of a penem antibiotic intermediate 4-BMA, which comprises the following steps: adding Zn powder, chlorosilane, aliphatic tertiary amine, zinc salt and 4-AA in a formula (I) into THF (tetrahydrofuran), uniformly stirring, dropwise adding a THF solution of alpha-haloamide with an induction group in a formula (II) for reaction, filtering the reaction solution, removing the zinc powder, and drying to obtain the penem antibiotic intermediate 4-BMA. Extracting the filtrate to obtain a THF phase, washing with an aqueous solution of potassium oxalate, and recovering THF to obtain a formula (III); and carrying out oxidative hydrolysis, sulfur dioxide quenching, sulfur dioxide acid regulation crystallization and recrystallization on the formula (III) to obtain the intermediate 4-BMA. According to the preparation method disclosed by the invention, a zinc salt is used as a catalyst during preparation of the formula (III), potassium oxalate is used for removing residual Zn (II) in a THF phase, SO2 is used for quenching hydrogen peroxide and acid regulation and crystallization of 4-BMA, the oxygenolysis problem of 4-BMA is solved, and the preparation method has the characteristics of greenness, safety and high efficiency, is strong in product competitive advantage and is suitable for industrial production.

The invention discloses an imipenem colorimetric detection method based on osmium nano-enzyme inhibition, and belongs to the technical field of analytical chemistry and biosensing. The method comprises the following steps: catalyzing H2O2 to oxidize TMB (Tetramethylbenzidine) to generate a blue product by utilizing the efficient peroxidase-like activity of alginate-modified osmium nano-enzyme (algin-Os); after ring opening of imipenem under an acidic condition, the catalytic activity of alginate-Os is specifically inhibited through dual mechanisms of metal-ligand coordination and free radical scavenging, so that the color development intensity of a solution is reduced, and the inhibition degree and the concentration of imipenem are in a dose-dependent relationship. According to the detection method, the linear range is 7.5 ng / mL-1120 ng / mL, the detection limit is as low as 2.5 nmol / L, the specificity is high, the anti-interference capacity is high, and the adding standard recovery rate of a serum sample is 90.5%-99.2%. The method is simple and convenient to operate, does not need complex instruments, is rapid in detection, can realize quantitative detection of imipenem, is suitable for clinical treatment drug monitoring, bedside detection and field detection in areas with limited resources, and has a relatively wide application prospect.

The present application relates to a Klebsiella pneumoniae bacteriophage, a bacteriophage composition thereof and application thereof, and belongs to the field of microorganisms. The present application provides a lytic bacteriophage Kp_WF01 infecting Klebsiella pneumoniae, and biological property research, morphological observation and whole-genome phylogenetic analysis are performed on the bacteriophage, and it is determined that the bacteriophage Kp_WF01 is a new species of Caudoviricetes Class Autographivirales Order Autotranscriptaviridae Family Przondovirus Genus. The in-vivo treatment effect and safety of the bacteriophage Kp_WF01 are evaluated by using a mouse model infected with CRKP, and the results show that the bacteriophage Kp_WF01 can rescue the CRKP-infected mouse, can be used as an effective therapeutic preparation against CRKP infection, and the treatment effect of the bacteriophage Kp_WF01 is better than that of imipenem.

The present application belongs to the technical field of complex enzyme. The present application provides a beta-lactamase complex enzyme capable of degrading various antibiotics, and a fixing method and application thereof. The preparation method of the complex enzyme comprises the following steps: extracting gene fragments of CTX-M type broad-spectrum beta-lactamase and VIM type metal-beta-lactamase from Klebsiella pneumoniae; obtaining the target gene fragments through PCR amplification, and constructing into a basic vector to obtain a recombinant vector; transforming the recombinant vector into host cells for heterologous expression; and through protein induction, SDS-PAGE protein gel electrophoresis and protein purification, the complex enzyme is obtained. The complex enzyme successfully degrades penicillins such as ampicillin, carbapenems such as imipenem, cephalosporins such as cefotaxime and other beta-lactams. The complex enzyme gene is successfully expressed in Escherichia coli, and the optimal fixing condition is obtained. The beta-lactamase complex enzyme is fixed under the optimal fixing condition, and can be repeatedly used.

The application discloses a beta-lactamase and a gene for coding the beta-lactamase, and further discloses an expression cassette, a recombinant carrier, a recombinant cell or a recombinant bacteria, and a construction method of the recombinant bacteria, and further discloses the application of the beta-lactamase, the gene for coding the beta-lactamase, the expression cassette, the recombinant carrier, the recombinant cell or the recombinant bacteria, and the construction method of the recombinant bacteria in removing beta-lactam antibiotic pollution in the environment. The beta-lactamase gene is transformed into escherichia coli, so that the escherichia coli can hydrolyze beta-lactam antibiotics in the environment, including ampicillin, cefazolin, cefotaxime, imipenem and amikacin, and has great application value in eliminating beta-lactam antibiotic pollution in the environment.

The invention discloses a multi-drug resistant pseudomonas aeruginosa PAS57 strain and an application of the multi-drug resistant pseudomonas aeruginosa PAS57 strain. The preservation number of the pseudomonas aeruginosa PAS57 is GDMCC No: 67235. The pseudomonas aeruginosa PAS57 can be used for preparing a bacterial strain. According to the application disclosed by the invention, a KirbyBauer (KB) drug sensitivity experiment shows that the PAS57 is resistant to the levofloxacin, the ciprofloxacin, the meropenem, the imipenem and the tobramycin. The strain disclosed by the invention can be used for screening a novel antibacterial drug which is effective to the multi-drug-resistant pseudomonas aeruginosa, and a new way is provided for development of drugs for treating diseases caused by the pseudomonas aeruginosa.

The application provides a combined drug for resisting klebsiella pneumoniae and application, and the combined drug for resisting klebsiella pneumoniae comprises a macrolide compound and a carbapenem antibiotic; the structural formula of the macrolide compound is shown in the following formula 1. The new macrolide compound found by the application can be synergized with imipenem, and the minimum inhibitory concentration of carbapenem-resistant klebsiella pneumoniae to imipenem can be significantly reduced to 0.78 μg / mL. In the synergistic concentration range, the macrolide compound shows good safety in vitro, and does not show cytotoxicity or hemolytic activity. Formula 1

The invention discloses a heterogeneous catalytic oxidation preparation method of a penem antibiotic intermediate. A raw material compound is subjected to a catalytic oxidation reaction in an organic solvent under the action of a catalyst and an oxidizing agent to generate a target product, wherein the catalyst is a ruthenium-based heterogeneous metal catalyst, and the oxidizing agent is peracetic acid. The preparation method disclosed by the invention has the characteristics of economy, high efficiency, convenience in separation and recovery and high yield.

The application belongs to the technical field of medicine, and particularly relates to a preparation method of imipenem impurity B, which comprises the following steps: 1) imipenem is added into water to obtain an imipenem suspension, concentrated sulfuric acid is added drop by drop and continuously stirred, after the solution is clarified, an alkaline solution is used to adjust the pH to neutral, and water is added to dilute to obtain an imipenem impurity B crude product solution; 2) the imipenem impurity B crude product solution is injected into a dynamic axial compression column system, gradient elution is carried out, and target component effluent is collected; 3) the target component effluent is freeze-dried to obtain imipenem impurity B pure product; the process (1) has short reaction time and high yield, concentrated sulfuric acid is added drop by drop into the imipenem solution until the solution is clarified, the reaction is completed, the degradation time is shortened, and the content of other impurities is reduced; (2) the preparation efficiency is high, the preparation process can realize continuous sampling, the preparation time is short, and the efficiency is high; (3) the purity is high, and the HPLC purity of the prepared imipenem impurity B can be as high as 97.6%.